Should Tata 1mg race to match 10-minute medicine delivery or differentiate through diagnostics and chronic care?

Introduction

Indian e-pharmacy has a new set of competitors. Quick-commerce companies have moved into medicines: Zepto launched a pharmacy with a 10-minute promise in 2025, Blinkit piloted prescription delivery, Swiggy partnered with PharmEasy, and PhonePe's Pincode launched fast medicine delivery. Apollo 24/7 is pushing fast delivery from its pharmacy network. Meanwhile, Tata 1mg has just reached a milestone: its core businesses turned EBITDA positive from December 2025, its ePharmacy business broke even in FY26, diagnostics crossed ₹600 crore in annualised revenue with double-digit margins, and its DTC health products business crossed ₹200 crore annualised revenue.

The question: should Tata 1mg race to match 10-minute medicine delivery, or differentiate through diagnostics and chronic care? This is a hard strategy question because the wrong choice could either erode hard-won profitability or let competitors capture the most frequent medicine needs.

Step 1

Clarify the Strategic Goals (3-4 minutes)

• I'm assuming the objective is to grow profitably and protect market position over three years, not to maximise order volume at any cost. Is that correct?

• Assumption: Yes. Tata Digital has shifted from GMV to monetisation across its businesses.
• Impact: Any speed strategy must have a path to positive unit economics.

• Which customer needs matter most?

• Assumption: Chronic medicines (high value, predictable), acute needs (urgent, lower value), and diagnostics (high margin).

• What resources can we use from the Tata Group?

• Assumption: BigBasket's dark stores and riders in some cities; Tata Neu for distribution and loyalty.

• What does "differentiate" mean?

• Assumption: Being the best platform for ongoing health management, not only the fastest delivery app.